Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 7/20 | 0.77 |
| ▸ | CTSS | P25774 | 9/20 | 0.59 |
| ▸ | CTSL | P07711 | 5/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464894 | 0.87 | CTSC (1.00) | CTSCCTSSCTSLCTSKCYP1A2 | |
| SCHEMBL3869381 | 0.79 | CTSC (0.67) | CTSCCTSSCTSLCTSKCYP1A2 | |
| SCHEMBL6063126 | 0.79 | CTSC (0.67) | CTSCCTSSCTSL | |
| SCHEMBL6627501 | 0.79 | CTSC (0.67) | CTSCCTSSCTSL | |
| SCHEMBL6061898 | 0.79 | CTSC (0.67) | CTSCCTSSCTSL | |
| SCHEMBL6063121 | 0.79 | CTSC (0.67) | CTSCCTSSCTSL | |
| SCHEMBL3895384 | 0.78 | CTSC (0.55) | CTSCCTSSCTSLCTSK | |
| SCHEMBL8863955 | 0.78 | CTSC (0.59) | CTSCCTSSCTSLCTSKCYP1A2 | |
| SCHEMBL6265571 | 0.78 | CTSC (0.59) | CTSCCTSSCTSLCTSKCYP1A2 | |
| SCHEMBL3497000 | 0.78 | CTSC (0.59) | CTSCCTSSCTSLCTSKCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730671-B2 | ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6608057-B2 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CYWIN CHARLES L (US) | 2002-07-11 | — | — | US | disclosed |
| US-6395897-B1 | DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | CTSC 13/4885CTSS 1/4885CTSL 12/4885 |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | CTSC 13/4885CTSS 1/4885CTSL 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.